- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
Patent holdings for IPC class C07D 213/71
Total number of patents in this class: 419
10-year publication summary
|
45
|
36
|
38
|
40
|
33
|
16
|
34
|
19
|
18
|
13
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Sumitomo Chemical Company, Limited | 8989 |
20 |
| ImmunoGen, Inc. | 376 |
14 |
| Amgen Inc. | 4486 |
13 |
| Novartis AG | 10172 |
12 |
| Bristol-myers Squibb Company | 4761 |
9 |
| Syngenta Crop Protection AG | 6789 |
8 |
| Takeda Pharmaceutical Company Limited | 2700 |
8 |
| F. Hoffmann-La Roche AG | 7792 |
7 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 177 |
7 |
| Ube Industries, Ltd. | 762 |
7 |
| The University of Queensland | 651 |
7 |
| Oxford Drug Design Limited | 11 |
7 |
| Arcus Biosciences, Inc. | 166 |
6 |
| Inflazome Limited | 84 |
6 |
| Baylor College of Medicine | 1014 |
5 |
| Sanofi | 4332 |
5 |
| BASF SE | 21318 |
4 |
| Board of Regents, The University of Texas System | 6177 |
4 |
| The Johns Hopkins University | 5948 |
4 |
| Vertex Pharmaceuticals Incorporated | 1577 |
4 |
| Other owners | 262 |